FDA 510(k) vs CDSCO Approval: 7 Key Differences If You Want to Sell in the US and India
Updated: 2 days ago
A medical device prototype is sitting on the table.
It works. The mechanism has been tested, the enclosure has gone through multiple iterations, clinicians have seen it, and the founders are finally beginning to talk about manufacturing.
Then someone asks: What do we need to sell this in the US?
And almost immediately: What changes if we want to sell it in India too?
The product hasn't changed. The regulatory journey has.
For the US, many medical devices reach the market through an FDA 510(k), where the central question is whether the device is substantially equivalent to an appropriate legally marketed predicate. India follows the Medical Devices Rules, 2017, with medical devices classified into four risk classes and different regulatory routes depending on factors including classification and whether the product is manufactured domestically or imported
So FDA 510(k) vs CDSCO isn't simply a comparison of two application processes.
If you already know that the US and India are both target markets, some of the decisions that will affect those regulatory journeys are being made much earlier-while the medical device is still being designed, engineered and prototyped.
That is where this comparison becomes interesting.
FDA 510(k) vs CDSCO: The Difference in 30 Seconds
Comparison Point | FDA 510(k) - United States | CDSCO / MDR 2017 -India |
Classification | Class I, II, III within the US framework | Class A, B, C, D |
510(k) basis | Substantial equivalence | No equivalent universal predicate-based pathway |
Predicate | Central to a 510(k) | Not the basis of the overall Indian framework |
Import | US-specific requirements apply | MD-14 application → MD-15 import licence |
Review | 90 FDA-day MDUFA decision goal | Depends on applicable route |
Key fee | $28,653 standard FY2027 510(k) user fee | Depends on applicable route |
For product teams | Regulatory strategy should be considered before design freeze | The same principle applies |
FDA's current 510(k) process sets a 90-FDA-day MDUFA decision goal, while CDSCO confirms India's four risk classes and the MD-14/MD-15 import-licence route.
1. FDA 510(k) and CDSCO Approval Are Not Two Versions of the Same Process
This is the first misconception worth clearing up.
An FDA 510(k) is a specific US premarket submission. It isn't another name for FDA approval, and not every medical device requires one.
For a 510(k), the manufacturer is seeking a determination that the new device is substantially equivalent to an appropriate legally marketed device. FDA's review considers the predicate comparison and supporting evidence.
India starts from a different structure.
Under the Medical Devices Rules, 2017, devices are classified according to risk:
Class A: Low risk
Class B: Low-moderate risk
Class C: Moderate-high risk
India's Medical Device Risk Framework
India's four medical device risk classes
The Medical Devices Rules, 2017 classify devices from low risk to high risk.
There is nuance even within that framework. For example, CDSCO lists an exemption of non-sterile and non-measuring Class A medical devices from the licensing regime.
So “How do I get CDSCO approval?” is often too broad a first question.
A more useful starting point is: What is the device? What is its intended use? How is it classified? And which regulatory route actually applies?
Those are questions worth answering while the product is still flexible.
2. A 510(k) May Begin With a Predicate. India Begins With a Different Regulatory Logic.
For a product following the FDA 510(k) pathway, identifying an appropriate predicate is fundamental to the substantial-equivalence strategy.
That creates an interesting challenge for product teams.
Once a predicate has been identified, it is easy to start treating the existing device as a design brief.
I don't think that's the right approach.
A predicate serves a regulatory purpose. Your product still needs to solve the user's problem.
If clinicians struggle with the grip on an existing product, there is no reason to repeat it. If an assembly is unnecessarily complicated, engineering can challenge it. If an existing device was designed around a very different healthcare environment, there may be room to rethink how the product works for your intended users.
FDA's own 510(k) framework does not require the new device simply to be a copy of its predicate. The submission must support the substantial-equivalence determination.
Understanding the predicate shouldn't mean inheriting every product decision the predicate made.
India's regulatory framework starts differently, with its A–D risk classification and the applicable route.
That means the same medical device can be headed toward two markets without the regulatory logic being identical.
3. FDA Gives Us Three Useful Numbers: 15, 60 and 90
The FDA 510(k) process contains some very concrete milestones.
For submissions subject to acceptance review, FDA describes an acceptance-review result within 15 days of receipt. A substantive interaction should occur within 60 calendar days, and the MDUFA goal for a 510(k) decision is 90 FDA days.
FDA 510(k): Key Review Milestones
15, 60, 90: Key FDA 510(k) review milestones
Selected milestones in FDA's published 510(k) process. The 90-day figure refers to FDA review days, not necessarily total calendar days.
4. The Number Founders Should Know Alongside 90 Is 180
FDA gives a submitter 180 calendar days from an Additional Information request to provide a complete response. If the response is not received within that period, FDA states that the submission will be considered withdrawn. The current process also uses a 180-day period for resolving specified hold or technical-screening deficiencies.
That gives us a more realistic picture of the 510(k) process:
How an FDA 510(k) Review Can Progress
510(k) submitted
↓
Acceptance / technical checks
↓
Substantive review
↓
By Day 60: Substantive interaction
Path A: Interactive review → FDA review continuesPath B: Additional Information request → FDA review clock stops
↓
Up to 180 calendar days for a complete AI response
↓
FDA review resumes
↓
90 FDA-day MDUFA decision goal
The important point isn't memorising every day in the process.
It's understanding that the regulatory submission depends on information and evidence that have been created during medical device development.
Testing results don't appear from nowhere. Neither do product specifications, device descriptions, engineering decisions or performance evidence.
By the time a 510(k) is being assembled, a large amount of the product story has already been written by the engineering team.
5. $28,653 Is a Very Visible Number. It Isn't the Whole Cost Story.
For FDA fiscal year 2027, which runs from October 1, 2026 to September 30, 2027, the standard 510(k) user fee is $28,653.
For an FDA-qualified small business, it is $7,163.
FDA FY2027 510(k) User Fees
$28,653 vs $7,163
FDA FY2027 standard and qualified small-business 510(k) user fees.
That's a difference of $21,490, with the qualified small-business fee approximately 75% lower than the standard fee.
FDA also lists an FY2027 annual establishment registration fee of $13,785 for establishments subject to that fee.
But this is where numbers can become misleading.
$28,653 is not the total cost of bringing a medical device through the US market-entry process.
It is the FDA's standard FY2027 510(k) user fee.
Depending on the product, the wider journey can include medical device design, engineering, prototyping, verification and validation, testing, quality activities, regulatory expertise and manufacturing preparation.
And there is another cost that is much harder to put into the original budget: discovering that the product itself needs to change.
6. India Adds Another Question: Are You Manufacturing Here or Importing?
Suppose the medical device has been developed outside India and the company now wants to enter the Indian market.
CDSCO states that the applicant for an import licence makes an application in Form MD-14, with the import licence granted in Form MD-15.
The basic route therefore looks like this:
Importing a Medical Device Into India
Determine the applicable device classification
→ Prepare the applicable regulatory and technical documentation
→ MD-14: Application for import licence
→ CDSCO / Central Licensing Authority review
→ MD-15: Import licence, if granted
→ Commercial import subject to applicable requirements
The route matters from a product-development perspective because regulatory documentation isn't entirely detached from engineering.
A team developing a medical device will already be making decisions around the product description, specifications, materials, variants, performance, manufacturing approach and labelling inputs.
If that information is scattered across old CAD versions, emails and prototype notes, assembling a coherent technical story later becomes unnecessarily difficult.
Good medical device development creates a product that is understood, not merely a prototype that works.
7. The Biggest Difference May Be What Happens Before Either Submission
This is the part of FDA 510(k) vs CDSCO that interests me most.
Consider two product teams.
The first designs its device, builds prototypes, selects materials, freezes the enclosure and starts talking to manufacturers. Only then does the regulatory conversation become serious.
The second establishes its intended use and target markets earlier. Its regulatory specialists determine the likely pathways and relevant requirements while the engineering team is still developing the product.
The regulatory and engineering teams still do different jobs.
But they are no longer working in sequence.
Where Regulatory Strategy Fits Into Medical Device Development
Clinical / User Need
→ Intended Use + Target Markets
→ Product Requirements
→ Medical Device Design
→ Engineering
→ Prototyping
→ Testing / Verification
→ Design for Manufacturing
→ Manufacturing Readiness
Regulatory strategy runs alongside this development process - not only after it.
That last line is the point.
A regulatory consultant shouldn't be expected to engineer the product.
A product-design company shouldn't pretend to be the regulatory consultant.
But if those two conversations begin too far apart, the product can end up paying for it.
Finding out that something needs to change while it is still a CAD model is one problem.
Finding it after prototypes have been validated, suppliers selected or tooling initiated is a very different one.
There is no credible universal percentage that tells us what every late design change will cost, and I wouldn't invent one simply to make the argument more dramatic.
The engineering consequences are enough.
Requirements stage: change the requirement.
Design stage: change the requirement and CAD.
Prototype stage: redesign, rebuild and potentially retest.
Later development: the same change may begin touching verification work,
documentation, suppliers, tooling, assembly and manufacturing preparation.
The later a fundamental issue is discovered, the more existing work it may affect.
FDA 510(k) vs CDSCO: 7 Differences at a Glance
Difference | FDA 510(k) - US | CDSCO / MDR 2017 - India |
1. Regulatory structure | 510(k) is a specific premarket pathway | Risk-based framework under MDR 2017 |
2. Classification | US Class I, II, III | Class A, B, C, D |
3. Core 510(k) concept | Substantial equivalence | No universal equivalent of the 510(k) predicate model |
4. Predicate | Central to the 510(k) pathway | Not the defining basis of the overall framework |
5. Review | 90 FDA-day MDUFA decision goal | Depends on the applicable route |
6. Import | US-specific requirements | MD-14 application → MD-15 import licence |
The regulatory systems aren't interchangeable. But for the engineering team, they point toward one common lesson:
Know where you intend to sell the product before too much of the product becomes difficult to change.
If You Want to Sell the Same Medical Device in the US and India, What Should You Do?
I wouldn't think of the development journey as:
Design → Prototype → Finished Product → FDA → CDSCO
By then, many important product decisions have already been made.
A more useful way to think about it is:
Clinical Need → Intended Use → Target Markets → Regulatory Strategy → Product Requirements → Design → Engineering → Prototyping → Testing → DFM → Regulatory Submission + Manufacturing Readiness
The exact process will vary by device.
The principle doesn't.
Knowing the intended markets earlier allows the team to ask better questions while the product is still flexible.
How is the device likely to be classified?
What is the intended use?
What testing may eventually be relevant?
What product evidence will need to be generated?
Which engineering decisions need better documentation?
Could a material, mechanism or interface choice create complications later?
Can one core product architecture support both intended markets?
Those questions don't replace regulatory expertise.
They make medical device development better informed.
One Product. Two Markets. Don't Design It Twice.
For me, that's the real takeaway from comparing FDA 510(k) and CDSCO.
A company planning to sell in India and the US doesn't need its engineering team pretending to be its regulatory consultant.
It needs its engineering and regulatory teams speaking early enough that one isn't undoing the work of the other.
Because changing a requirement on paper is relatively easy.
Changing CAD takes more work.
Rebuilding a medical device prototype takes more again.
Changing something after verification can have wider implications.
Changing tooling when everyone thought the product was ready for manufacturing can become a very different conversation.
So the most important difference between FDA 510(k) and CDSCO may not be found on an application form.
It may show up months earlier in a product-development meeting.
Regulatory strategy determines what the product needs to demonstrate. Medical device design and engineering determine what product you actually have to demonstrate it with.
They are different disciplines.
Good product development gives them a reason to talk early.
Developing a Medical Device for India, the US-or Both?
At Inspire Design, we have worked across 60+ healthcare product development projects, supporting clinicians, startups and healthcare companies through medical device design, engineering, prototyping and Design for Manufacturing.
We don't replace your regulatory consultant. We work on the product.
Whether you have an early clinical idea, existing CAD, a working medical device prototype, or a product that needs engineering support before manufacturing, bringing product engineering and regulatory thinking together early can reduce the chances of discovering difficult design changes much later.
Book a call with Inspire Design now to discuss where your medical device stands today and what it needs to become next.
Frequently Asked Questions About FDA 510(k) vs CDSCO
1. Is CDSCO approval the same as an FDA 510(k)?
No. An FDA 510(k) is a specific US premarket-notification pathway involving a substantial-equivalence determination. India regulates medical devices under the Medical Devices Rules, 2017, with devices classified as Class A, B, C or D according to risk. CDSCO
2. What are the four medical device classes in India?
India uses Class A (low risk), Class B (low-moderate risk), Class C (moderate-high risk) and Class D (high risk). CDSCO
3. How long does an FDA 510(k) take?
FDA has a 90 FDA-day MDUFA decision goal for a 510(k). This is not necessarily 90 total calendar days because periods when the submission is on hold for an Additional Information request are excluded from the FDA review-day calculation.
4. What happens if FDA asks for additional information?
An Additional Information request places the submission on hold. FDA gives the submitter 180 calendar days from the request to provide a complete response; otherwise, the submission is considered withdrawn.
5. How much is the FDA 510(k) fee in 2027?
For FY2027, the standard FDA 510(k) user fee is $28,653. The fee for an FDA-qualified small business is $7,163.
6. What forms are used to import a medical device into India?
CDSCO states that the applicant makes an import-licence application in Form MD-14, with the licence granted in Form MD-15. CDSCO
7. Does every medical device need an FDA 510(k)?
No. The applicable US regulatory pathway depends on the device and its classification. Some devices may be exempt from 510(k), while other products may follow other premarket pathways.
8. Should regulatory planning happen before medical device prototyping?
For a product intended for regulated markets, understanding the likely regulatory pathway early can help the development team identify relevant requirements, evidence and testing considerations while the medical device design is still flexible. The regulatory strategy itself should be developed with appropriately qualified regulatory expertise.
Disclaimer: This article is for general educational purposes and discusses the product-development implications of FDA and CDSCO regulatory frameworks. It is not regulatory or legal advice. Requirements depend on the specific medical device, intended use, classification, target market and manufacturing/import arrangements.
About the Author
Kunal Bijlani
Kunal Bijlani is the Co-founder of Inspire Design, a product design and engineering company working with clinicians, startups and healthcare companies on medical device design and development.
Through Inspire Design's work across 60+ healthcare product development projects, Kunal has worked with teams moving from early clinical ideas through product design, engineering, medical device prototyping and Design for Manufacturing.
His focus is on building products where user needs, engineering realities and manufacturing requirements are considered early-before they become expensive problems later in development.
Comments